PubMed · 2015 · 19 citations · 0 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyChemotherapy Drug AdministrationChemotherapy In Hematologic MalignanciesDose Adjustment In Oncology5-Fluorouracil Therapy5-Fluorouracil TreatmentCapecitabine-based TherapyDihydrofolate Reductase MutationDihydropyrimidine Dehydrogenase DeficiencyDihydropyrimidine Dehydrogenase TestingDpyd GenotypeDpyd Genotyping
BACKGROUND: Dihydropyrimidine dehydrogenase (DPD) degrades approximately 85% of administered 5-fluorouracil (5-FU). With a reported high mortality rate, chemotherapy is generally contraindicated for patients with DPD deficiency. PATIENTS AND METHODS: Chemotherapy was initiated for a 73-year-old man with DPD deficiency. Capecitabine was administered in incrementally increasing doses, beginning with a single pill while monitoring plasma 5-FU concentration, and neutrophil and platelet counts. RESULTS: DPD protein level was 2.35 U/mg. After increasing the capecitabine dose to 1,800 mg, oxaliplatin and bevacizumab were added. Subsequent DPD protein measurement showed that the level had increased to approximately 12-fold the one before chemotherapy. Sequencing of all 23 exons of DPYD gene revealed a mutation of guanine to thymine in exon 11 (1156 G>T). CONCLUSION: This is the first report to indicate that DPD activity can be induced. These findings may provide early indications of a new method for chemotherapy for DPD-deficient patients.